改良发热不良事件管理算法与辅助达拉非尼联合曲美替尼治疗患者发热相关结局改善相关:COMBI-APlus 主要结果
COMBI-APlus 是一项开放标签 IIIb 期试验,在高危已切除 III 期 BRAF V600E/K 突变黑色素瘤患者中评估改良发热管理算法,患者接受最多 12 个月辅助达拉非尼联合曲美替尼治疗。主要终点复合率(3/4 级发热、因发热住院或因发热永久停药)为 8.0%(95%CI 5.9%-10.6%),优于历史 COMBI-AD 对照的 20.0%(95%CI 16.3%-24.1%),达到主要终点。
要点
- 改良发热管理算法使复合发热结局发生率为 8.0%(95%CI 5.9%-10.6%),历史对照为 20.0%(95%CI 16.3%-24.1%)。
- 3/4 级发热发生率为 3.8%,因发热住院率为 4.3%,因发热永久停药率为 2.4%。
- 估计 12 个月无复发生存率为 91.8%(95%CI 89.0%-93.9%)。
核心结论
- 改良发热管理算法似乎可降低严重发热结局的发生率,使患者能够在家管理发热,并有助于患者维持治疗。
研究设计与样本
- COMBI-APlus 是一项开放标签 IIIb 期试验,评估改良发热管理算法在高危已切除 III 期 BRAF V600E/K 突变黑色素瘤患者中的应用,患者接受最多 12 个月辅助达拉非尼联合曲美替尼治疗。
主要发现
- 主要终点复合率(3/4 级发热、因发热住院或因发热永久停药)为 8.0%(95%CI 5.9%-10.6%),历史 COMBI-AD 对照为 20.0%(95%CI 16.3%-24.1%)。
- 3/4 级发热发生率为 3.8%,因发热住院率为 4.3%,因发热永久停药率为 2.4%。
- 估计 12 个月无复发生存率为 91.8%(95%CI 89.0%-93.9%)。
- 最常见不良事件与 COMBI-AD 一致,14.7% 的患者因不良事件永久停药。
关键数值与推荐
- 发热(体温≥38°C)或疑似复发发热出现发热综合征时,两种药物均中断;患者无症状≥24 小时后以相同剂量重新开始治疗。
- 主要终点为 3/4 级发热、因发热住院或因发热永久停药的复合率,对比历史 COMBI-AD 对照(20.0%;95%CI 16.3%-24.1%)。
临床怎么用
- 改良发热管理算法似乎可减少严重发热结局,使患者能够在家管理发热,并有助于患者维持治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COMBI-AD demonstrated long-term benefit of adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600E/K-mutant melanoma; however, 9% of patients permanently discontinued therapy due to pyrexia. COMBI-APlus evaluated whether an adapted pyrexia management algorithm reduces high-grade pyrexia and pyrexia-related adverse outcomes. METHODS: COMBI-APlus is an open-label, phase IIIb trial evaluating an adapted pyrexia management algorithm in patients with high-risk resected stage III BRAF V600E/K-mutant melanoma treated with up to 12 months of adjuvant dabrafenib plus trametinib. Both drugs were interrupted for pyrexia (temperature ≥38°C) or the occurrence of pyrexia syndrome for suspected recurrent pyrexia. Treatment was restarted at the same dose once patients were symptom free for ≥24 h. The primary endpoint was the composite rate of grade 3/4 pyrexia, hospitalisation due to pyrexia, or permanent discontinuation due to pyrexia versus historical COMBI-AD control (20.0%; 95% confidence interval [CI], 16.3%-24.1%). RESULTS: At data cutoff (5 October 2020), COMBI-APlus met its primary endpoint of significant improvement in the composite rate of pyrexia (8.0% [95% CI, 5.9%-10.6%]), with rates of 3.8% for grade 3/4 pyrexia, 4.3% for hospitalisation due to pyrexia, and 2.4% for discontinuation due to pyrexia. Estimated 12-month relapse-free survival was 91.8% (95% CI, 89.0%-93.9%). The most common adverse events were consistent with those in COMBI-AD, and 14.7% of patients permanently discontinued treatment due to adverse events. CONCLUSIONS: The adapted pyrexia management algorithm appears to reduce the incidence of severe pyrexia outcomes, enables patients to manage pyrexia at home, and helps patients remain on treatment. CLINICAL TRIAL REGISTRATION: NCT03551626.
引用
- Atkinson V, Robert C, Grob JJ, et al. Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. Eur J Cancer. 2022. PMID: 35042070. doi:10.1016/j.ejca.2021.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。